Centogene N.V. announced the company reached its initial recruitment and genetic testing milestone in the observational EFRONT Study, being conducted to advance the genetic understanding of frontotemporal dementia (FTD). The EFRONT Study has been conducted with support from Alector, a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases, including FTD. Having met this milestone, CENTOGENE will continue to work with its extensive network of 30,000 physicians and enroll patients in the EFRONT Study under its Cento-FTD Program to provide timely diagnosis and further unlock insights into this neurodegenerative disorder.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4889 USD | +1.88% | +7.24% | -59.26% |
Apr. 02 | Centogene Gets Nasdaq Noncompliance Notice | MT |
Mar. 19 | Centogene, Takeda Pharmaceutical Collaborate on Lysosomal Storage Disorders Diagnostics | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-59.26% | 13.62M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- CNTG Stock
- News Centogene N.V.
- Centogene N.V.'s Frontotemporal Dementia Genetic Study, EFRONT, Reaches Initial Patient Enrollment Milestone